No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
COO240621C140000
- 0.38
- 0.000.00%
15min DelayTrading Jun 6 12:40 ET
0.00High0.00Low
0.00Open0.38Pre Close0 Volume1 Open Interest140.00Strike Price0.00Turnover372.24%IV54.61%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.38Extrinsic Value100Contract SizeAmericanOptions Type0.0461Delta0.0044Gamma238.94Leverage Ratio-0.3758Theta0.0002Rho11.02Eff Leverage0.0057Vega
Intraday
- 5D
- Daily
News
Are The Cooper Companies, Inc.'s (NASDAQ:COO) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
It is hard to get excited after looking at Cooper Companies' (NASDAQ:COO) recent performance, when its stock has declined 6.6% over the past three months. It seems that the market might have complet
Cooper Companies Second Quarter 2024 Earnings: EPS Misses Expectations
Wells Fargo's Christopher Harvey's Mid-Cap Portfolio
Decoding The Cooper Companies Inc (COO): A Strategic SWOT Insight
Cooper Companies | 10-Q: Quarterly report
Tech Stocks Crumble As Wall Street's 5-Week Rally Ends; Bonds Offer Safe Haven As Growth Worries Reemerge: What's Driving Markets Friday?
Bears knocked on Wall Street's door again Friday, sending large-cap tech stocks lower despite the Fed's favorite inflation measure meeting expectations.Both the S&P 500 and the Nasdaq 100 index are se
Comments
Investors maintain a high P/E ratio for Cooper Companies despite earnings decline, buoyed by strong forecasted growth. This is expected to continue supporting the share price.
Why Investors Shouldn't Be Surprised By The Cooper Companies, Inc.'s (NASDAQ:COO) P/E 1
Jonathan Banas, executive vice president and chief financial officer, expressed delight at the appointment of Nudd, praising her as an invaluable and energetic leader within the finance function at Cooper Standard.
Cooper Companies' decreasing ROCE and stagnant sales despite reinvestment don't suggest a potential multi-bagger. The past five-year return indicates awareness of these trends. Consider other options for a multi-bagger.
Baird advocates medtech companies such as Alcon, Stryker, and Cooper due to product and pricing strengths. Belief is strong in Alcon's 2024 margin possibilities, Stryker's premium pricing and predicted robust orthopedic demand, and projected revenue growth for Boston Scientific and Axonics.
Cooper Companies' high P/E ratio is backed by robust earnings growth outlook. Shareholders are holding onto their stocks due to the expected superior future earnings growth.
Read more